UK tissues authority advises on traceability measures after adverse reaction case:
This article was originally published in Clinica
Executive Summary
The UK's Human Tissue Authority is sending out a notice to all establishments storing tissue for transplantation to remind them of their responsibilities with regard to traceability The measures follow the case of a UK patient treated overseas being admitted to hospital with an adverse reaction to treatment using stem cells. The HTA has decided that the material should be retained to be tested, if necessary, as part of any future investigation.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.